Conformation and topology of amyloid β-protein adsorbed on a tethered artificial membrane probed by surface plasmon field-enhanced fluorescence spectroscopy

Journal of Structural Biology

Volumn 168, Issue 1, 2009, Pages 117-124

  Song, Haipeng ^a   Ritz, Sandra ^a   Knoll, Wolfgang ^b   Sinner, Eva Kathrin ^a,c  

^a MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

^b AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^c INSTITUTE OF MATERIALS RESEARCH AND ENGINEERING   (Singapore)

Author keywords

Alzheimer's disease (AD); Amyloid peptide (A ); Immunoassay; Melatonin; SPFS; SPS

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; MELATONIN; MONOCLONAL ANTIBODY; PEPTIDE;

ADSORPTION; ALPHA HELIX; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; ARTIFICIAL MEMBRANE; BETA SHEET; BINDING AFFINITY; BINDING KINETICS; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; IMMUNOASSAY; LIPID BILAYER; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; SENILE PLAQUE; SURFACE PLASMON RESONANCE;

ABSORPTION; AMYLOID BETA-PROTEIN; LIPID BILAYERS; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL; SPECTROMETRY, FLUORESCENCE; SURFACE PLASMON RESONANCE;

EID: 69249213873     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2009.06.020     Document Type: Article

References (35)

1. Adessi C., Frossard M.J., Boissard C., Fraga S., Bieler S., Ruckle T., Vilbois F., Robinson S.M., Mutter M., Banks W.A., et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem. 278 (2003) 13905-13911
2. Aisenbrey C., Borowik T., Bystrom R., Bokvist M., Lindstrom F., Misiak H., Sani M.A., and Grobner G. How is protein aggregation in amyloidogenic diseases modulated by biological membranes?. Eur. Biophys. J. 37 (2008) 247-255
3. Bieler S., and Soto C. Beta-sheet breakers for Alzheimer's disease therapy. Curr. Drug Targets 5 (2004) 553-558
4. Busciglio J., Lorenzo A., and Yankner B.A. Methodological variables in the assessment of beta amyloid neurotoxicity. Neurobiol. Aging Neurobiol. Aging 13 (1992) 609-612
5. Busciglio J., Lorenzo A., and Yankner B.A. β-Amyloid fibrils induce tau-phosphorylation and loss of microtubule binding. Neuron 14 (1995) 879-888
6. Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A., and Wanker E.E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. & Mol. Biol. 15 6 (2008) 558-566
7. Finder V.H., and Glockshuber R. Amyloid-β aggregation. Neurodegenerative Diseases 4 1 (2007) 13-27
8. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M.L., and Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4 (1998) 827-831
9. Gordon J.G., and Swalen J.D. The effect of thin organic films on the surface plasma resonance on gold. Optics Commun. 22 (1977) 374-376
10. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
11. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J. Alzheimers Dis. 9 (2006) 151-153
12. Hartly D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., and Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19 (1999) 8876-8884
13. Ji S.R., Wu Y., and Sui S.F. Cholesterol is an important factor affecting the membrane insertion of β-amyloid peptide (Aβ1-40), which may potentially inhibit the fibril formation. J. Biol. Chem. 277 (2002) 6273-6279
14. Kakio A., Nishimoto S., Yanagisawa K., Kozutsumi Y., and Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276 (2001) 24985-24990
15. Kakio A., Nishimoto S., Yanagisawa K., Kozutsumi Y., and Matsuzaki K. Interactions of amyloid β-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41 (2002) 7385-7390
16. Kim J.E., and Lee M.Y. Fullerene inhibits β-amyloid peptide aggregation. Biochem. Biophys. Res. Commun. 303 (2003) 576-579
17. Knoll W., Park H., Sinner E.K., Yao D., and Yu F. Supramolecular interfacial architectures for optical biosensing with surface plasmons. Surf. Sci. 570 (2004) 30-42
18. Liebermann T., and Knoll W. Surface-plasmon field-enhanced fluorescence spectroscopy. Colloids and Surfaces A: Phys. chem. and Engineering Aspects 171 11 (2000) 5-130
19. Mahfoud R., Garmy N., Maresca M., Yahi N., Puigserver A., and Fantini J. Identification of a common sphingolipid-binding domain in Alzheimer, Prion, and HIV-1 Proteins. J. Biol. Chem. 277 (2002) 11292-11296
20. McLaurin J., and Chakrabartty A. Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. European Journal of Biochemistry/FEBS 245 2 (1997) 355-363
21. Muchowski P.J., and Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosc. 6 1 (2005) 11-22
22. Muhs A., Hickman D.T., Pihlgren M., Chuard N., et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. PNAS 104 (2007) 9810-9815
23. Pappolla M., Bozner P., Soto C., Shao H., Robakis N.K., Zagorski M., Frangione B., and Ghiso J. Inhibition of Alzheimer beta - fibrillogenesis by melatonin. J. Biol. Chem. 273 (1998) 7185-7188
24. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13 (1993) 1676-1687
25. Rzepecki P., Nagel-Steger L., Feuerstein S., Linne U., Molt O., Zadmard R., Aschermann K., Wehner M., Schrader T., and Riesner D. Prevention of Alzheimer's disease-associated Aβ aggregation by rationally designed nonpeptidic β-sheetlLigands. J. Biol. Chem. 279 (2004) 47497-47505
26. Selkoe D.J. The cell biology of amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8 (1998) 447-453
27. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M.G., Whaley J., Swindlehurst C., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 (1992) 325-327
28. Shida C.S., Costa E.X., Ito A.S., and Lamyfreund M.T. Interaction of the aromatic hormone melatonin with lipid-membranes. Biophys. J. 66 (1994) A57
29. Skene D.J., Vivien-Roels B., Sparks D.L., Hunsaker J.C., Pévet P., Ravid D., and Swaab D.F. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res. 528 (1990) 170-174
30. Skribanek Z., Baláspiri L., and Mák M. Interaction between synthetic amyloid-β-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J. Mass Spectrom. 36 (2001) 1226-1229
31. Song H., Sinner E.K., and Knoll W. Peptide-tethered bilayer lipid membranes and their interaction with amyloid beta-peptide. Biointerphases 2 (2007) 151-158
32. 2H NMR study. Biophys. J. 85 (2003) 1013-1024
33. Yamamoto N., Igbavboa U., Shimada Y., Ohno-Iwashita Y., Kobayashi M., Wood W.G., Fujita S.C., and Yanagisawa K. Accelerated Aβ aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 569 (2004) 135-139
34. Yu F., Yao D., and Knoll W. Surface plasmon field-enhanced fluorescence spectroscopy studies of the interaction between an antibody and its surface-coupled antigen. Anal. Chem. 75 (2003) 2610-2617
35. Yu W., Zou K., Gong J.S., Ko M., Yanagisawa K., and Michikawa M. Oligomerization of amyloid β-protein occurs during the isolation of lipid rafts. J. Neurosci. Res. 80 (2005) 114-119